Delivery route, MyD88 signaling and cross-priming events determine the anti-tumor efficacy of an adenovirus based melanoma vaccine

Vaccine

Volumn 29, Issue 12, 2011, Pages 2313-2321

  Hangalapura, Basav N ^a   Oosterhoff, Dinja ^a   Gupta, Tarun ^a   de Groot, Jan ^a   Wijnands, Pepijn G J T B ^a   van Beusechem, Victor W ^a   den Haan, Joke ^a   TÜting, Thomas ^b   van den Eertwegh, Alfons J M ^a   Curiel, David T ^c   Scheper, Rik J ^a   de Gruijl, Tanja D ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF BONN   (Germany)

^c and Clinical Center   (United States)

Author keywords

Adenovirus; Administration route; Melanoma

Indexed keywords

ADENOVIRUS VECTOR; MELANOMA VACCINE; MYELOID DIFFERENTIATION FACTOR 88;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER MODEL; CONTROLLED STUDY; CROSS PRESENTATION; DRUG EFFICACY; LYMPH NODE; MELANOMA; MELANOMA B16; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADENOVIRIDAE; ANIMALS; ANTIGEN-PRESENTING CELLS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CROSS-PRIMING; DENDRITIC CELLS; INJECTIONS, INTRADERMAL; INJECTIONS, INTRAVENOUS; LYMPH NODES; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYELOID DIFFERENTIATION FACTOR 88;

EID: 79951813688     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.01.022     Document Type: Article

References (54)

1. Cocco C., Pistoia V., Airoldi I. New perspectives for melanoma immunotherapy: role of IL-12. Curr Mol Med 2009, 9:459-469.
2. Steitz J., Bruck J., Gambotto A., Knop J., Tuting T. Genetic immunization with a melanocytic self-antigen linked to foreign helper sequences breaks tolerance and induces autoimmunity and tumor immunity. Gene Ther 2002, 9:208-213.
3. Sharma A., Li X., Bangari D.S., Mittal S.K. Adenovirus receptors and their implications in gene delivery. Virus Res 2009, 143:184-194.
4. Douglas J.T. Adenoviral vectors for gene therapy. Mol Biotechnol 2007, 36:71-80.
5. Tuting T., Steitz J., Bruck J., Gambotto A., Steinbrink K., DeLeo A.B., et al. Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity. J Gene Med 1999, 1:400-406.
6. Tormo D., Ferrer A., Bosch P., Gaffal E., Basner-Tschakarjan E., Wenzel J., et al. Therapeutic efficacy of antigen-specific vaccination and toll-like receptor stimulation against established transplanted and autochthonous melanoma in mice. Cancer Res 2006, 66:5427-5435.
7. Steitz J., Tormo D., Schweichel D., Tuting T. Comparison of recombinant adenovirus and synthetic peptide for DC-based melanoma vaccination. Cancer Gene Ther 2006, 13:318-325.
8. Steitz J., Bruck J., Knop J., Tuting T. Adenovirus-transduced dendritic cells stimulate cellular immunity to melanoma via a CD4(+) T cell-dependent mechanism. Gene Ther 2001, 8:1255-1263.
9. Parkhurst M.R., Fitzgerald E.B., Southwood S., Sette A., Rosenberg S.A., Kawakami Y. Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2). Cancer Res 1998, 58:4895-4901.
10. Perricone M.A., Claussen K.A., Smith K.A., Kaplan J.M., Piraino S., Shankara S., et al. Immunogene therapy for murine melanoma using recombinant adenoviral vectors expressing melanoma-associated antigens. Mol Ther 2000, 1:275-284.
11. Bloom M.B., Perry-Lalley D., Robbins P.F., Li Y., el-Gamil M., Rosenberg S.A., et al. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J Exp Med 1997, 185:453-459.
12. He Y., Zhang J., Donahue C., Falo L.D. Skin-derived dendritic cells induce potent CD8(+) T cell immunity in recombinant lentivector-mediated genetic immunization. Immunity 2006, 24:643-656.
13. Belz G.T., Smith C.M., Eichner D., Shortman K., Karupiah G., Carbone F.R., et al. Cutting edge: conventional CD8 alpha+ dendritic cells are generally involved in priming CTL immunity to viruses. J Immunol 2004, 172:1996-2000.
14. Allan R.S., Smith C.M., Belz G.T., van Lint A.L., Wakim L.M., Heath W.R., et al. Epidermal viral immunity induced by CD8 alpha+ dendritic cells but not by Langerhans cells. Science 2003, 301:1925-1928.
15. Smith C.M., Belz G.T., Wilson N.S., Villadangos J.A., Shortman K., Carbone F.R., et al. Cutting edge: conventional CD8 alpha+ dendritic cells are preferentially involved in CTL priming after footpad infection with herpes simplex virus-1. J Immunol 2003, 170:4437-4440.
16. Zhu J., Huang X., Yang Y. Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and -independent pathways. J Virol 2007, 81:3170-3180.
17. Iwasaki A., Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004, 5:987-995.
18. Huleatt J.W., Jacobs A.R., Tang J., Desai P., Kopp E.B., Huang Y., et al. Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity. Vaccine 2007, 25:763-775.
19. Akazawa T., Masuda H., Saeki Y., Matsumoto M., Takeda K., Tsujimura K., et al. Adjuvant-mediated tumor regression and tumor-specific cytotoxic response are impaired in MyD88-deficient mice. Cancer Res 2004, 64:757-764.
20. O'Neill L.A., Bowie A.G. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol 2007, 7:353-364.
21. Sheahan T., Morrison T.E., Funkhouser W., Uematsu S., Akira S., Baric R.S., et al. MyD88 is required for protection from lethal infection with a mouse-adapted SARS-CoV. PLoS Pathog 2008, 4:e1000240.
22. Appledorn D.M., Patial S., McBride A., Godbehere S., Van Rooijen N., Parameswaran N., et al. Adenovirus vector-induced innate inflammatory mediators, MAPK signaling, as well as adaptive immune responses are dependent upon both TLR2 and TLR9 in vivo. J Immunol 2008, 181:2134-2144.
23. Hartman Z.C., Kiang A., Everett R.S., Serra D., Yang X.Y., Clay T.M., et al. Adenovirus infection triggers a rapid, MyD88-regulated transcriptome response critical to acute-phase and adaptive immune responses in vivo. J Virol 2007, 81:1796-1812.
24. Philpott N.J., Nociari M., Elkon K.B., Falck-Pedersen E. Adenovirus-induced maturation of dendritic cells through a PI3 kinase-mediated TNF-alpha induction pathway. Proc Natl Acad Sci USA 2004, 101:6200-6205.
25. van Beusechem V.W., van Rijswijk A.L., van Es H.H., Haisma H.J., Pinedo H.M., Gerritsen W.R. Recombinant adenovirus vectors with knobless fibers for targeted gene transfer. Gene Ther 2000, 7:1940-1946.
26. Sharma S., Stolina M., Lin Y., Gardner B., Miller P.W., Kronenberg M., et al. T cell-derived IL-10 promotes lung cancer growth by suppressing both T cell and APC function. J Immunol 1999, 163:5020-5028.
27. Wexler H. Accurate identification of experimental pulmonary metastases. J Natl Cancer Inst 1966, 36:641-645.
28. 25+ regulatory T-cell-inactivation in combination with adenovirus vaccines enhances T-cell responses and protects mice from tumor challenge. Cancer Gene Ther 2007, 14:201-210.
29. Kusser K.L., Randall T.D. Simultaneous detection of EGFP and cell surface markers by fluorescence microscopy in lymphoid tissues. J Histochem Cytochem 2003, 51:5-14.
30. Samsom J.N., van der Marel A.P., van Berkel L.A., van Helvoort J.M., Simons-Oosterhuis Y., Jansen W., et al. Secretory leukoprotease inhibitor in mucosal lymph node dendritic cells regulates the threshold for mucosal tolerance. J Immunol 2007, 179:6588-6595.
31. Schweichel D., Steitz J., Tormo D., Gaffal E., Ferrer A., Buchs S., et al. Evaluation of DNA vaccination with recombinant adenoviruses using bioluminescence imaging of antigen expression: impact of application routes and delivery with dendritic cells. J Gene Med 2006, 8:1243-1250.
32. Okada N., Masunaga Y., Okada Y., Mizuguchi H., Iiyama S., Mori N., et al. Dendritic cells transduced with gp100 gene by RGD fiber-mutant adenovirus vectors are highly efficacious in generating anti-B16BL6 melanoma immunity in mice. Gene Ther 2003, 10:1891-1902.
33. Eggert A.A., Schreurs M.W., Boerman O.C., Oyen W.J., de Boer A.J., Punt C.J., et al. Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. Cancer Res 1999, 59:3340-3345.
34. Sheasley-O'Neill S.L., Brinkman C.C., Ferguson A.R., Dispenza M.C., Engelhard V.H. Dendritic cell immunization route determines integrin expression and lymphoid and nonlymphoid tissue distribution of CD8 T cells. J Immunol 2007, 178:1512-1522.
35. Mullins D.W., Sheasley S.L., Ream R.M., Bullock T.N., Fu Y.X., Engelhard V.H. Route of immunization with peptide-pulsed dendritic cells controls the distribution of memory and effector T cells in lymphoid tissues and determines the pattern of regional tumor control. J Exp Med 2003, 198:1023-1034.
36. Lambert L.A., Gibson G.R., Maloney M., Durell B., Noelle R.J., Barth R.J. Intranodal immunization with tumor lysate-pulsed dendritic cells enhances protective antitumor immunity. Cancer Res 2001, 61:641-646.
37. Huang D., Pereboev A.V., Korokhov N., He R., Larocque L., Gravel C., et al. Significant alterations of biodistribution and immune responses in Balb/c mice administered with adenovirus targeted to CD40(+) cells. Gene Ther 2008, 15:298-308.
38. + T cell response induced by adenoviral vector immunization is critically influenced by virus dose and route of vaccination. J Immunol 2010, 184:4431-4439.
39. Bonnotte B., Gough M., Phan V., Ahmed A., Chong H., Martin F., et al. Intradermal injection, as opposed to subcutaneous injection, enhances immunogenicity and suppresses tumorigenicity of tumor cells. Cancer Res 2003, 63:2145-2149.
40. Santosuosso M., McCormick S., Xing Z. Adenoviral vectors for mucosal vaccination against infectious diseases. Viral Immunol 2005, 18:283-291.
41. Chen K., Cerutti A. Vaccination strategies to promote mucosal antibody responses. Immunity 2010, 33:479-491.
42. Noureddini S.C., Curiel D.T. Genetic targeting strategies for adenovirus. Mol Pharm 2005, 2:341-347.
43. Setoguchi Y., Jaffe H.A., Danel C., Crystal R.G. Ex vivo and in vivo gene transfer to the skin using replication-deficient recombinant adenovirus vectors. J Invest Dermatol 1994, 102:415-421.
44. Prasad S.A., Norbury C.C., Chen W., Bennink J.R., Yewdell J.W. Cutting edge: recombinant adenoviruses induce CD8 T cell responses to an inserted protein whose expression is limited to nonimmune cells. J Immunol 2001, 166:4809-4812.
45. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392:245-252.
46. Allan R.S., Waithman J., Bedoui S., Jones C.M., Villadangos J.A., Zhan Y., et al. Migratory dendritic cells transfer antigen to a lymph node-resident dendritic cell population for efficient CTL priming. Immunity 2006, 25:153-162.
47. Garg S., Oran A., Wajchman J., Sasaki S., Maris C.H., Kapp J.A., et al. Genetic tagging shows increased frequency and longevity of antigen-presenting, skin-derived dendritic cells in vivo. Nat Immunol 2003, 4:907-912.
48. Yamaguchi T., Kawabata K., Koizumi N., Sakurai F., Nakashima K., Sakurai H., et al. Role of MyD88 and TLR9 in the innate immune response elicited by serotype 5 adenoviral vectors. Hum Gene Ther 2007, 18:753-762.
49. Zhao Y., De Trez C., Flynn R., Ware C.F., Croft M., Salek-Ardakani S. The adaptor molecule MyD88 directly promotes CD8 T cell responses to vaccinia virus. J Immunol 2009, 182:6278-6286.
50. Takeda K., Kaisho T., Akira S. Toll-like receptors. Annu Rev Immunol 2003, 21:335-376.
51. Asprodites N., Zheng L., Geng D., Velasco-Gonzalez C., Sanchez-Perez L., Davila E. Engagement of Toll-like receptor-2 on cytotoxic T-lymphocytes occurs in vivo and augments antitumor activity. FASEB J 2008, 22:3628-3637.
52. Rahman A.H., Cui W., Larosa D.F., Taylor D.K., Zhang J., Goldstein D.R., et al. MyD88 plays a critical T cell-intrinsic role in supporting CD8 T cell expansion during acute lymphocytic choriomeningitis virus infection. J Immunol 2008, 181:3804-3810.
53. Quigley M., Martinez J., Huang X., Yang Y. A critical role for direct TLR2-MyD88 signaling in CD8 T-cell clonal expansion and memory formation following vaccinia viral infection. Blood 2009, 113:2256-2264.
54. + T-cell population in LCMV-infected mice. J Gen Virol 2009, 90:423-431.